A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis

References

• Cleveland DW, Rothstein JD. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nature Reviews Neuroscience. 2001;2:806–19.
   PubMed Web of Science ®Google Scholar
• Nickolay B, Tatiana B, Janet MD. On the mechanisms of neuroprotection by creatine and phosphocreatine. Journal of Neurochemistry. 2001;76:425–34.
   PubMed Web of Science ®Google Scholar
• O'Gorman E, Beutner G, Wallimann T, Brdiczka D. Differential effects of creatine depletion on the regulation of enzyme activities and on creatine-stimulated mitochondrial respiration in skeletal muscle, heart, and brain. Biochim Biophys Acta. 1996;1276:161–70.
   PubMed Web of Science ®Google Scholar
• Xu CJ, Klunk WE, Kanfer JN, Xiong Q, Miller G, Pettegrew JW. Phosphocreatine-dependent glutamate uptake by synaptic vesicles. Journal of Biological Chemistry. 1996; 271:13435–40.
   PubMed Web of Science ®Google Scholar
• Lawler JM, Barnes WS, Wu G, Song W, Demaree S. Direct antioxidant properties of creatine. Biochemical and Biophysical Research Communications. 2002;290:47–52.
   PubMed Web of Science ®Google Scholar
• Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, . Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nature Medicine. 1999;5:347.
   PubMed Web of Science ®Google Scholar
• Dedeoglu A, Kubilus J, Yang L, Ferrante K, Hersch S, Beal M, . Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem. 2003;85:1359–67.
   PubMed Web of Science ®Google Scholar
• Ferrante RJ, Andreassen OA, Jenkins BG, Dedeoglu A, Kuemmerle S, Kubilus JK, . Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000;20:4389–97.
   PubMed Web of Science ®Google Scholar
• Matthews R, Yang L, Jenkins B, Ferrante R, Rosen B, Kaddurah-Daouk R, . Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci. 1998;18:156–63.
   PubMed Web of Science ®Google Scholar
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, . A clinical trial of creatine in ALS. Neurology. 2004;63:1656–61.
   PubMed Web of Science ®Google Scholar
• Rosenfeld J, King RM, Jackson CE, Bedlack RS, Barohn RJ, Dick A, . Creatine monohydrate in ALS: effects on strength, fatigue, respiratory status and ALSFRS. Amyotroph Lateral Scler. 2008;9:266–72.
   PubMed Web of Science ®Google Scholar
• Groeneveld G, Veldink J, van der Tweel I, Kalmijn S, Beijer C, de Visser M, . A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437–45.
   PubMed Web of Science ®Google Scholar
• Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, van Leemputte M, . Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology. 2003;61:925–30.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AHV, . Creatine therapy for Huntington's disease: clinical and MRS findings in a one-year pilot study. Neurology. 2003;61:141–2.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Blamire AM, Manners DN, Rajagopalan B, Styles P, Schapira AHV, . High-dose creatine therapy for Huntington disease: a two-year clinical and MRS study. Neurology. 2005;64:1655–6.
   PubMed Web of Science ®Google Scholar
• Hersch SM. Creatine safety, tolerability, and efficacy in Huntington's disease: CREST-E http://dietary-supplements infonihgov/Funding/abstractaspx?g=5U01AT000613-08+.
   Google Scholar
• Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘Clinical limits of amyotrophic lateral sclerosis’. J Neurol Sci. 1994;124:96–107.
   PubMed Web of Science ®Google Scholar
• van der Kouwe AJ, Benner T, Fischl B, Schmitt F, Salat DH, Harder M, . On-line automatic slice positioning for brain MR imaging. NeuroImage. 2005;27:222–30.
   PubMed Web of Science ®Google Scholar
• Ogg R, Kingsley P, Taylor J. WET, a T1- and B1-insensitive water-suppression method for in vivo localized 1H NMR spectroscopy. J Magn Reson B. 1994;104:1–10.
   PubMedGoogle Scholar
• Kong J, Xu Z. Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci. 1998;18: 3241–50.
   PubMed Web of Science ®Google Scholar
• Dupuis L. Oxidative stress sensitivity in ALS muscle cells. Exp Neurol. 2009;220:219–23.
   PubMed Web of Science ®Google Scholar
• Murata T, Ohtsuka C, Terayama Y. Increased mitochondrial oxidative damage in patients with sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2008;267:66–9.
   PubMed Web of Science ®Google Scholar
• Debska-Vielhaber G, Minin I, Schaoler S, Kunz W, Vielhaber S. Mitochondrial damage in fibroblasts of patients with ALS. 20th International Symposium on ALS/MND; 2009: Amyotroph Lateral Scler; 2009, 115.
   Google Scholar
• Persky A, Brazeau G, Hochhaus G. Pharmacokinetics of the dietary supplement creatine. Clinical Pharmacokinetics. 2003;42:557–74.
   PubMed Web of Science ®Google Scholar
• Rothstein J, Kuncl R, Chaudry V, Clawson L, Cornblath D, Coyle J, . Excitatory amino acids in amyotrophic lateral sclerosis. Ann Neurol. 1991;20:224–5.
   Google Scholar
• Spreux-Varoquaux O, Bensimon G, Lacomblez L, Salachas F, Pradat PF, Le Forestier N, . Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. J Neurol Sci. 2002;193:73–8.
   PubMed Web of Science ®Google Scholar
• Di Bernardo AB, Cudkowicz ME. Translating preclinical insights into effective human trials in ALS. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2006; 1762:1139–49.
   PubMed Web of Science ®Google Scholar
• Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron. 1988;1:623–34.
   PubMed Web of Science ®Google Scholar
• Bensimon G, Lacomblez L, Meininger V, The ALSRSG. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330:585–91.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh P, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Spindler M, Meyer K, Stromer H, Leupold A, Boehm E, Wagner H, . Creatine kinase-deficient hearts exhibit increased susceptibility to ischemia-reperfusion injury and impaired calcium homeostasis. Am J Physiol Heart Circ Physiol. 2004;287:1039–45.
   Web of Science ®Google Scholar